|

Olive Oil Supplementation for Heart Failure With Reduced Ejection Fraction

RECRUITINGN/ASponsored by Old Dominion University
Actively Recruiting
PhaseN/A
SponsorOld Dominion University
Started2026-07-01
Est. completion2027-12-31
Eligibility
Age18 Years – 85 Years
Healthy vol.Accepted
Locations1 site

Summary

The OLEA-HF study aims to explore whether daily supplementation of extra-virgin olive oil (EVOO) for 12 weeks during participation in a cardiac rehabilitation program (standard of care) is feasible in patients with heart failure with reduced ejection fraction (HFrEF). The investigators will also determine the effects of EVOO on functional capacity and quality of life.

Eligibility

Age: 18 Years – 85 YearsHealthy volunteers accepted
Inclusion Criteria:

* Diagnosed with HFrEF with left ventricular ejection fraction ≤35 %.
* Referred to and enrolled in the standard cardiac rehabilitation program at Sentara Cardiac Rehabilitation Center, but has not yet initiated/started cardiac rehabilitation (i.e., has not attended the first cardiac rehab session).
* Able and willing to comply with study procedures and provide informed consent.

Exclusion Criteria:

* Co-morbidity expected to limit survival (e.g., terminal illness).
* End-stage renal disease.
* Unstable fluid overload.
* Current pregnancy (self-disclose).
* Habitual use of EVOO greater than 4 tablespoons per day.
* Known allergy or sensitivity to olive oil or its components.
* Unwillingness or inability to incorporate EVOO or dietary recommendations.

Conditions2

Heart DiseaseHeart Failure With Reduced Ejection Fraction (HFrEF)

Locations1 site

Strelitz Diabetes Center (Williams Hall)
Norfolk, Virginia, 23510
Salvatore Carbone, PhD, RDN7574467149scarbone@odu.edu

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.